Literature DB >> 11881034

Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction.

Y Z Zhu1, Y C Zhu, J Li, H Schäfer, W Schmidt, T Yao, T Unger.   

Abstract

We investigated the haemodynamic parameters and the regulation of cardiac mRNA levels of the angiotensin receptor subtypes, AT1 and AT2, by the AT,-receptor antagonist losartan in rat heart during the acute phase of myocardial infarction. AT1- andAT2-receptor mRNA levels markedly increased at 30 minutes and peaked at 24 hours post myocardial infarction (12.6-fold increase for AT1- and 17.2-fold increase for AT2 compared with controls). Losartan significantly reduced mean blood pressure in sham-operated rats and decreased mean blood pressure and left ventricular end-diastolic pressure in myocardial infarction rats. However, the AT,- andAT2-receptor mRNA levels of losartan-treated rats showed a pattern similar to that of water-treated rats. The time-dependent increase of AT1- and AT2-receptor mRNA levels is associated with the early remodelling process of non-infarcted myocardium post MI and is independent of AT1-receptor blockade.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11881034     DOI: 10.3317/jraas.2000.039

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  9 in total

1.  Protective roles of quercetin in acute myocardial ischemia and reperfusion injury in rats.

Authors:  Hong-Bo Jin; Yong-Bin Yang; Ying-Li Song; Yong-chun Zhang; Yu-Rong Li
Journal:  Mol Biol Rep       Date:  2012-10-08       Impact factor: 2.316

Review 2.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

Review 3.  Are angiotensin receptor blockers neuroprotective?

Authors:  Christa Thöne-Reineke; Mathias Zimmermann; Christian Neumann; Maxim Krikov; Jun Li; Nadja Gerova; Thomas Unger
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

4.  Hydrogen sulfide attenuates cardiac dysfunction in a rat model of heart failure: a mechanism through cardiac mitochondrial protection.

Authors:  Xianli Wang; Qian Wang; Wei Guo; Yi Zhun Zhu
Journal:  Biosci Rep       Date:  2011-04       Impact factor: 3.840

5.  Anti-ischaemic effects of bilobalide on neonatal rat cardiomyocytes and the involvement of the platelet-activating factor receptor.

Authors:  Stefanie Maerz; Chun-Hua Liu; Wei Guo; Yi-Zhun Zhu
Journal:  Biosci Rep       Date:  2011-10       Impact factor: 3.840

6.  Cardioprotective effects and pharmacokinetic properties of a controlled release formulation of a novel hydrogen sulfide donor in rats with acute myocardial infarction.

Authors:  Ba Hieu Tran; Chengrong Huang; Qiuyan Zhang; Xu Liu; Shizhou Lin; Hongrui Liu; Shujun Wang; Yi Zhun Zhu
Journal:  Biosci Rep       Date:  2015-04-30       Impact factor: 3.840

7.  Cardioprotective Effects of Curcumin-Nisin Based Poly Lactic Acid Nanoparticle on Myocardial Infarction in Guinea Pigs.

Authors:  Williams E E Nabofa; Oluwadamilola O Alashe; Oyetunde T Oyeyemi; Alfred F Attah; Ademola A Oyagbemi; Temidayo O Omobowale; Adeolu A Adedapo; Akinola R A Alada
Journal:  Sci Rep       Date:  2018-11-09       Impact factor: 4.379

Review 8.  Clinical Application of Melatonin in the Treatment of Cardiovascular Diseases: Current Evidence and New Insights into the Cardioprotective and Cardiotherapeutic Properties.

Authors:  Mohammad Hossein Pourhanifeh; Ehsan Dehdashtian; Azam Hosseinzadeh; Seyed Hashem Sezavar; Saeed Mehrzadi
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-14       Impact factor: 3.727

9.  Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction.

Authors:  Andrea Babick; Donald Chapman; Shelley Zieroth; Vijayan Elimban; Naranjan S Dhalla
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.